Please use this identifier to cite or link to this item:
Title: Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.
Austin Authors: Loo, Sun;Lim, Andrew Boon Ming ;Lee, Sze Ting ;Grigg, Andrew P 
Affiliation: Molecular Imaging and Therapy
Clinical Haematology
Issue Date: 2023 2022
Publication information: Clinical Lymphoma, Myeloma & Leukemia 2023; 23(3)
Abstract: In patients with relapsed/refractory lymphoma after first line therapy, chemosensitivity to salvage chemotherapy is the main determinant of outcome pre-autologous stem cell transplant . With novel therapies not yet widely available and poor responses to conventional dose salvage therapy such as ifosfamide, carboplatin, and etoposide (ICE) in patients with early relapse within 12 months and primary refractory disease, there is capacity to dose intensify ifosfamide and etoposide (augmented ICE).
DOI: 10.1016/j.clml.2022.11.010
Journal: Clinical lymphoma, myeloma & leukemia
PubMed URL: 36707275
ISSN: 2152-2669
Type: Journal Article
Subjects: DLBCL
Salvage therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.